Vertex Reports Second Quarter 2026 Financial Results

About this update from Vortex Energy Corp.

Vertex Reports Second Quarter 2026 Financial Results .bwalignc { text-align: center; list-style-position: inside } .bwalignl { text-align: left } .bwalignr { text-align: right; list-style-position: inside } .bwblockalignl { margin-left: 0px; margin-right: auto } .bwcellpmargin { margin-bottom: 0px; margin-top: 0px } .bwdoublebottom { border-bottom: double black 2.25pt } .bwlistdisc { list-style-type: disc } .bwnowrap { white-space: nowrap } .bwpadb3 { padding-bottom: 4px } .bwpadb4 { padding-bottom: 5px } .bwpadl0 { padding-left: 0px } .bwpadl3 { padding-left: 15px } .bwpadl6 { padding-left: 30px } .bwpadl9 { padding-left: 45px } .bwpadr0 { padding-right: 0px } .bwsinglebottom { border-bottom: solid black 1pt } .bwtablemarginb { margin-bottom: 10px } .bwuline { text-decoration: underline } .bwvertalignb { vertical-align: bottom } .bwvertalignt { vertical-align: top } .bwwidth1 { width: 1% } .bwwidth10 { width: 10% } .bwwidth100 { width: 100% } .bwwidth2 { width: 2% } .bwwidth20 { width: 20% } .bwwidth4 { width: 4% } .bwwidth53 { width: 53% } .bwwidth56 { width: 56% } .bwwidth59 { width: 59% } .bwwidth73 { width: 73% } .bwwidth9 { width: 9% } — Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 billion — — Continued progress across research and development pipeline; povetacicept PDUFA date November 30th — — Entered into agreement to acquire Crinetics Pharmaceuticals, with closing anticipated in the third quarter of 2026 — Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance. “Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pillar, further diversifying our portfolio,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “With this breadth of commercial and clinical opportunities, we look forward to bringing more medicines to more patients around the globe and in so doing, creating long-term value.”...

View stock analysis, news, and events for Vortex Energy Corp.